Actin in dendritic spines: connecting dynamics to function
Encouraging early data suggesting that patients transitioning from weekly to less frequent GLP-1 dosing can maintain weight loss and metabolic improvements
In this blog, well break down the role of these medications, explore their pros and cons, and help you understand if they might be a good option for you
The approval marked a major milestone for the GLP-1 market by expanding the use of GLP-1 receptor agonists beyond diabetes management into obesity treatment and significantly accelerating market growth In May 2022, Eli Lilly and Company received U.S
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial
Quick Answer: Leg pain is not a recognised adverse reaction in the UK Summary of Product Characteristics for Wegovy, though some patients report musculoskeletal discomfort potentially related to rapid weight loss, electrolyte imbalances, or increased physical activity rather than direct drug effects
